Current Market Access to Avsola, Inflectra and Remicade

While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.

NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 7/12/21.

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/12/WordPress-Featured_AdobeStock_183561967.jpg
December 2

Obesity Management Targets Complex Disease via New Drugs, Better Awareness

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/12/AdobeStock_198051301-scaled.jpeg
December 2

HHS Rule Not Only Empowers Patients but Also Benefits Other Industry Stakeholders

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-payer-portrait.jpg
December 2

MMIT Payer Portrait: Cambia Health Solutions

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today